OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test tha… Read more
OncoCyte Corp (OCX) - Net Assets
Latest net assets as of March 2025: $10.22 Million USD
Based on the latest financial reports, OncoCyte Corp (OCX) has net assets worth $10.22 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($60.36 Million) and total liabilities ($50.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.22 Million |
| % of Total Assets | 16.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | -136.66% |
| 10-Year Change | -217.83% |
| Growth Volatility | 259.52 |
OncoCyte Corp - Net Assets Trend (2013–2024)
This chart illustrates how OncoCyte Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OncoCyte Corp (2013–2024)
The table below shows the annual net assets of OncoCyte Corp from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-12.27 Million | -147.96% |
| 2023-12-31 | $25.59 Million | -25.36% |
| 2022-12-31 | $34.29 Million | -47.42% |
| 2021-12-31 | $65.22 Million | +94.78% |
| 2020-12-31 | $33.48 Million | +8.58% |
| 2019-12-31 | $30.84 Million | +800.91% |
| 2018-12-31 | $3.42 Million | -22.26% |
| 2017-12-31 | $4.40 Million | -55.35% |
| 2016-12-31 | $9.86 Million | -5.33% |
| 2015-12-31 | $10.42 Million | +1069.93% |
| 2014-12-31 | $-1.07 Million | -129.71% |
| 2013-12-31 | $3.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to OncoCyte Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34012600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $338.24 Million | % |
| Other Comprehensive Income | $21.00K | % |
| Total Equity | $-12.27 Million | 100.00% |
OncoCyte Corp Competitors by Market Cap
The table below lists competitors of OncoCyte Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Atlan Holdings Bhd
KLSE:7048
|
$24.51 Million |
|
Zaklad Budowy Maszyn ZREMB-CHOJNICE S.A.
WAR:ZRE
|
$24.52 Million |
|
Kolon Globalco
KO:003070
|
$24.52 Million |
|
Tay Ninh Rubber JSC
VN:TRC
|
$24.53 Million |
|
EDAG Engineering Group AG
XETRA:ED4
|
$24.50 Million |
|
Kuya Silver Corporation
OTCQB:KUYAF
|
$24.50 Million |
|
Barinthus Biotherapeutics plc
NASDAQ:BRNS
|
$24.50 Million |
|
Dr Peng Telecom and Media Group Co Ltd
SHG:600804
|
$24.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OncoCyte Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 25,594,000 to -12,274,000, a change of -37,868,000 (-148.0%).
- Net loss of 60,663,000 reduced equity.
- Share repurchases of 5,389,000 reduced equity.
- New share issuances of 27,814,000 increased equity.
- Other comprehensive income decreased equity by 28,000.
- Other factors increased equity by 398,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-60.66 Million | -494.24% |
| Share Repurchases | $5.39 Million | -43.91% |
| Share Issuances | $27.81 Million | +226.61% |
| Other Comprehensive Income | $-28.00K | -0.23% |
| Other Changes | $398.00K | +3.24% |
| Total Change | $- | -147.96% |
Book Value vs Market Value Analysis
This analysis compares OncoCyte Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $11.14 | $3.16 | x |
| 2014-12-31 | $-3.31 | $3.16 | x |
| 2015-12-31 | $9.92 | $3.16 | x |
| 2016-12-31 | $7.43 | $3.16 | x |
| 2017-12-31 | $2.92 | $3.16 | x |
| 2018-12-31 | $1.81 | $3.16 | x |
| 2019-12-31 | $12.02 | $3.16 | x |
| 2020-12-31 | $10.23 | $3.16 | x |
| 2021-12-31 | $14.67 | $3.16 | x |
| 2022-12-31 | $6.19 | $3.16 | x |
| 2023-12-31 | $3.35 | $3.16 | x |
| 2024-12-31 | $-0.94 | $3.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OncoCyte Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3225.04%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-148.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -96.68% | 0.00% | 0.00x | 2.29x | $-3.86 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.88 Million |
| 2015 | -83.85% | 0.00% | 0.00x | 1.22x | $-9.78 Million |
| 2016 | -113.24% | 0.00% | 0.00x | 1.46x | $-12.15 Million |
| 2017 | -440.04% | 0.00% | 0.00x | 2.32x | $-19.82 Million |
| 2018 | -460.24% | 0.00% | 0.00x | 2.78x | $-16.10 Million |
| 2019 | -72.41% | -139556.25% | 0.00x | 1.29x | $-25.41 Million |
| 2020 | -89.39% | -2461.51% | 0.02x | 1.66x | $-33.28 Million |
| 2021 | -98.28% | -829.52% | 0.05x | 2.45x | $-70.62 Million |
| 2022 | -214.16% | -7665.97% | 0.01x | 2.92x | $-76.87 Million |
| 2023 | -108.54% | -1848.37% | 0.02x | 2.93x | $-30.34 Million |
| 2024 | 0.00% | -3225.04% | 0.05x | 0.00x | $-59.44 Million |
Industry Comparison
This section compares OncoCyte Corp's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OncoCyte Corp (OCX) | $10.22 Million | -96.68% | 4.91x | $24.51 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |